Periodic Reporting for period 1 - SALAS (MALLEABLE SURGICAL RETRACTOR FOR COMPLETE EXPOSURE OF MITRAL VALVE)
Reporting period: 2017-01-01 to 2017-06-30
Due to aging of population and development of emerging countries, mitral valve surgical procedures are growing market worldwide expecting to double its actual size for 2030. In this scenario, ANSABERE in collaboration with Dr. Anas Sarraj (surgeon of Hospital La Princesa in Madrid and associate professor of Autonomous University of Madrid) has developed an innovative device for both mitral conventional and MIS surgery, called SALAS, that provide better and complete exposition of the mitral valve and its ring from inside the left atrium.
The instrument allows to surgeon to adjust and adapt the working area due to the use of the lateral flap and the malleability of the arms of the invention."
Objective: To analyse the market and confirm the value proposition, determine the business model, identify stakeholders to integrate them into the demonstration process, and confirm business projections to ensure return on investment and the future sustainability of the company.
Tasks: Three different tasks have been implemented during the project execution:
- Task 1: MARKET STUDY
- Task 2: FREEDOM TO OPERATE, VALUE PROPOSITION AND BUSINESS MODEL
- Task 3: COST, REVENUES AND FUNDING SCHEME
- Task 4: FEASIBILITY STUDY
- Task 5: DEMONSTRATION AGREEMENTS"
Mentioned characteristics that provide SALAS instrument, allow to surgeon to have a better working area. Therefore, this solution reduces considerably operation and recovery times (around 20%) and consequently operation costs and patients pain. Those advantages will contribute to improve the offer of a quality health system.
It is really important to show economic benefit of using SALAS device for hospitals. Several studies reflect that mitral surgery cost for hospital since patient is admitted until abandon the hospital is around 30.000€. So, having reduced 20% of operation and recovery times, it can be assumed that total operation cost is reduced in 20% as well.
"